Skip to main content
Article thumbnail
Location of Repository

Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within the European Prospective Investigation into Cancer and Nutrition (EPIC)

By Ruth C. Travis, Francesca L. Crowe, Naomi E. Allen, Paul N. Appleby, Andrew W. Roddam, Anne Tjønneland, Anja Olsen, Jakob Linseisen, Rudolf Kaaks, Heiner Boeing, Janine Kröger, Antonia Trichopoulou, Vardis Dilis, Dimitrios Trichopoulos, Paolo Vineis, Domenico Palli, Rosario Tumino, Sabina Sieri, H. Bas Bueno-de-Mesquita, Fränzel J. B. van Duijnhoven, María-Dolores Chirlaque, Aurelio Barricarte, Nerea Larrañaga, Carlos A. González, Marcial V. Argüelles, Maria-José Sánchez, Pär Stattin, Göran Hallmans, Kay-Tee Khaw, Sheila Bingham, Sabina Rinaldi, Nadia Slimani, Mazda Jenab, Elio Riboli and Timothy J. Key


Results from the majority of studies show little association between circulating concentrations of vitamin D and prostate cancer risk, a finding that has not been demonstrated in a wider European population, however. The authors examined whether vitamin D concentrations were associated with prostate cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (1994–2000). Serum concentrations of 25-hydroxyvitamin D were measured in 652 prostate cancer cases matched to 752 controls from 7 European countries after a median follow-up time of 4.1 years. Conditional logistic regression models were used to calculate odds ratios for prostate cancer risk in relation to serum 25-hydroxyvitamin D after standardizing for month of blood collection and adjusting for covariates. No significant association was found between 25-hydroxyvitamin D and risk of prostate cancer (highest vs. lowest quintile: odds ratio = 1.28, 95% confidence interval: 0.88, 1.88; P for trend = 0.188). Subgroup analyses showed no significant heterogeneity by cancer stage or grade, age at diagnosis, body mass index, time from blood collection to diagnosis, or calcium intake. In summary, the results of this large nested case-control study provide no evidence in support of a protective effect of circulating concentrations of vitamin D on the risk of prostate cancer

Topics: Original Contributions
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1997). 1 alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev.
    2. A generalization of the paired t-test.
    3. (2007). A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med.
    4. (1994). Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res.
    5. Asymptomatic incidence and duration of prostate cancer.
    6. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries.
    7. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
    8. (2001). Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev.
    9. (1993). et al.Vitamin Dand prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev.
    10. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr.
    11. European Prospective Investigation into Cancer and Nutrition: validity studies on dietary assessment methods. Int J Epidemiol. 1997;26(suppl 1):S1–S5.
    12. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25- hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev.
    13. (1990). Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res.
    14. (2007). Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev.
    15. Medical progress: vitamin D deficiency.
    16. Phase II study of 1ahydroxyvitamin D2 in the treatment of advanced androgenindependent prostate cancer. Clin Cancer Res.
    17. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
    18. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study.
    19. (2005). Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D are related to the phenotype of Gc (vitamin Dbinding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int.
    20. (2004). Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer.
    21. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control.
    22. (2000). Prostate cancer risk andprediagnosticserum25-hydroxyvitaminDlevels(Finland). Cancer Causes Control.
    23. (2007). Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective.
    24. (1995). Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev.
    25. Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
    26. (1998). Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control.
    27. (1998). The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res.
    28. Vitamin D and calcium deficits predispose for multiple chronic diseases.
    29. (1993). Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology.
    30. (2006). Vitamin D physiology. Prog Biophys Mol Biol.
    31. (2007). Vitamin D receptor (VDR) gene polymorphisms and haplotypes,
    32. (2007). Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.